Advanced Biomed

There is no operating revenue, so there is no demonstrated ability to raise prices or defend margins. In the prior biochip plan, pricing power would have required regulatory approvals and clinical adoption; the strategic sale of the Taiwan R&D unit removes that near‑term path.

In the new AI direction, the firm will be a price‑taker in a competitive market until it proves differentiated value.